SILVER SPRING
Vabysmo label updated for macular edema treatment extension
- Sponsor
- Genentech $RHHBY
- Drug
- Vabysmo · faricimab-svoa
- Indication
- macular edema following retinal vein occlusion
FDA approved an updated label for Vabysmo (faricimab-svoa) to extend treatment duration for macular edema following retinal vein occlusion beyond six months.
What this means
Vabysmo is an eye injection that treats swelling in the retina by blocking two proteins that cause leaky blood vessels. The FDA updated its label to allow longer intervals between doses for patients with macular edema after retinal vein occlusion, potentially reducing the number of injections needed. This could mean fewer doctor visits for patients while maintaining vision protection.
Drug Watch — recent news on Vabysmo
- nAMD and DME: Faricimab matches aflibercept visual acuity gains in pivotal trials - Vera Health
- Intra-anterior chamber faricimab for iris neovascularization: a case report - springermedicine.com
- Roche Holding stock steadies as Vabysmo trial success and Alzheimer’s blood test underpin H1 2026 - AD HOC NEWS
- Roche’s Vabysmo delivers sustained vision gains in two-year PCV data - Indian Pharma Post
- Vabysmo shows sustained two-year results in difficult-to-treat eye disease subtype - The Pharma Letter
Sponsor Watch — recent news on Genentech
- What does the EU have that the U.S. does not?
- CHMP recommends EU approval of Roche’s Ocrevus for children and adolescents with relapsing multiple sclerosis
- Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug
- Roche agrees to $1bn deal with Dualitas for bispecific antibody research
- BioNTech Threw in the Towel on Its Colorectal Cancer Vaccine Trial. Should Investors Be Worried?